US 11,952,384 B2
Anti-tumor compound and preparation method and use thereof
Yu Zhang, Shanghai (CN); Zhongyuan Zhu, Shanghai (CN); Haiqing Hua, Shanghai (CN); Bing Li, Shanghai (CN); Jian Li, Shanghai (CN); Shengchao Lin, Shanghai (CN); Xi Li, Shanghai (CN); and Hongxia Shen, Shanghai (CN)
Assigned to DUALITY BIOLOGICS (SUZHOU) CO., LTD., Shanghai (CN)
Filed by DUALITY BIOLOGICS (SUZHOU) CO., LTD., Shanghai (CN)
Filed on Dec. 28, 2022, as Appl. No. 18/147,070.
Application 18/147,070 is a continuation of application No. 17/828,433, filed on May 31, 2022, granted, now 11,607,459.
Application 17/828,433 is a continuation of application No. 17/825,090, filed on May 26, 2022, granted, now 11,685,742.
Application 17/825,090 is a continuation of application No. PCT/CN2021/121721, filed on Sep. 29, 2021.
Claims priority of application No. 202011061580.7 (CN), filed on Sep. 30, 2020.
Prior Publication US 2023/0212182 A1, Jul. 6, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 491/22 (2006.01); A61K 47/65 (2017.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01)
CPC C07D 491/22 (2013.01) [A61K 47/65 (2017.08); A61K 47/6803 (2017.08); A61K 47/6855 (2017.08); A61P 35/00 (2018.01)] 20 Claims
 
1. A compound of general formula (III-E) or a tautomer, a mesomer, a racemate, an enantiomer or a diastereoisomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof,

OG Complex Work Unit Chemistry
wherein R1 is selected from the group consisting of: —O—, —(R2)N— and —S—;
X is -L1-CH2—C(O)—;
L1 is —(C(R3a)(R3b))m—;
wherein R2 is hydrogen, or a C1-6 aliphatic group optionally substituted with R; each R3a and each R3b are independently hydrogen, protium, deuterium, tritium, halogen, —NO2, —CN, —OR, —SR, or a C1-6 aliphatic group optionally substituted with R;
wherein R is hydrogen, protium, deuterium, tritium, halogen, —NO2, —CN, —OH, —SH, or —NH2;
m is selected from the group consisting of integers from 1 to 5, and R3a and R3b are not both hydrogen in each —C(R3a)(R3b)—.